Vanda Posts $22.6M Q3 Loss as Cash Burn Continues
VNDA is trading near its 52-week low of $3.79 (5.5% above the low) on elevated volume (1.9× avg).
Summary
Vanda reported a third-quarter loss of $22.6M, or 37 cents a share, a narrower loss than the $62.5M posted in Q2 but still a substantial cash drain for a company with a roughly $242M market cap. Third-quarter revenue came in at $69.8M, up 24% on the strength of Fanapt sales. The Q2 collapse was driven by HETLIOZ sales falling 66%, and cash reserves had already dropped to $170M by the June quarter, so another quarter of losses eats further into a thin balance sheet. The pipeline has been mixed: positive Phase 3 data for Hetlioz in Delayed Sleep-Wake Phase Disorder in late September and for tradipitant in GLP-1-related vomiting yesterday, offset by the October halt of VQW-765 after a Phase 3 failure. The company also updated its 2026 revenue outlook.
At the time of this announcement, VNDA was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $241.9M. The 52-week trading range was $3.79 to $9.94. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.